KPTI News and Press, Karyopharm Therapeutics Inc. From 12/09/20

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with this event. For further details see: Karyopharm Therapeutics (KPTI) Presents At American Society of Hematology - Slideshow

Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting NEWTON, Mass. , Dec. 7, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a comme...

Karyopharm Presents XPOVIO® (Selinexor) Data in Multiple Myeloma and Diffuse Large-B-Cell Lymphoma at the American Society of Hematology 2020 Annual Meeting NEWTON, Mass. , Dec. 7, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage p...

Antengene has submitted new drug applications ((NDA)) for XPOVIO (selinexor, ATG-010) being co-developed by Karyopharm Therapeutics (KPTI) to the regulatory authorities in Singapore and Australia for the treatment of adult patients with relapsed or refractory multiple myeloma (...

Karyopharm Announces Investor and Analyst Event at the American Society of Hematology 2020 Annual Meeting NEWTON, Mass. , Dec. 1, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer thera...

Karyopharm Expands Board of Directors and Executive Leadership Team and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -- Biotechnology Industry Veteran Chen Schor Appointed to Board of Directors -- -- Stephen Mitchener Named Chief Business Officer, Bringing ...

Karyopharm Announces Ongoing Phase 3 SIENDO Study of XPOVIO® (Selinexor) in Patients with Endometrial Cancer Passes Planned Interim Futility Analysis: Data and Safety Monitoring Board Recommends the Study Should Proceed as Planned Without Any Modifications -- Company Expect...

Karyopharm Therapeutics ([[KPTI]] -1.5%) has announced presentation of positive results from the Phase 3 portion of SEAL study evaluating single agent, oral XPOVIO (selinexor) versus matching placebo in patients with liposarcoma at the Connective Tissue Oncology Society 2020 Annual Meeting. P...

Karyopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology Society 2020 Annual Meeting -- Twice-Weekly XPOVIO® (selinexor) Demonstrates a Statistically Significant Improvement in Median PFS (Hazard Ratio=0.70, p=0.023) in Patients w...

Xpovio is showing good uptake after about a year on the market. The second line multiple myeloma indication will likely be added next Spring. Karyopharm looks substantially undervalued even without factoring in any of the pipeline beyond Xpovio’s first three indications. ...